Michael Burkes, Chief Financial Officer of Natera, Inc. (NASDAQ:NTRA), recently executed a series of stock transactions as detailed in a Form 4 filing with the Securities and Exchange Commission. On January 22, Burkes sold a total of 25,931 shares of Natera's common stock, generating approximately $4.28 million. The shares were sold at prices ranging from $164.95 to $171.95 per share. The transaction comes as Natera, now valued at $22.7 billion, trades near its 52-week high after an impressive 158% return over the past year. InvestingPro analysis indicates the stock is currently overvalued based on its Fair Value calculations.
In earlier transactions, Burkes acquired 2,667 shares of Natera common stock on January 20 and 21 through the vesting of restricted stock units, which were recorded at no cost. Following these transactions, Burkes holds 109,665 shares of Natera stock directly. According to InvestingPro data, the company maintains a GOOD overall financial health score, with liquid assets exceeding short-term obligations. Discover 10+ additional exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Natera Inc . has expanded its patent infringement litigation against NeoGenomics (NASDAQ:NEO), Inc., adding an additional patent to the ongoing lawsuit over the RaDaR assay. The company also reported a significant 64% increase in Q3 revenue year-over-year, hitting a record $439.8 million. Analyst firms TD (TSX:TD) Cowen, Baird, and Jefferies have expressed confidence in Natera's future performance, maintaining favorable ratings and raising their price targets.
In response to these developments, Natera has revised its full-year revenue guidance to between $1.61 billion and $1.64 billion. The company has also amended an agreement with its Executive Chairman, Dr. Rabinowitz, outlining the terms of his continued role.
However, Natera faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:GH). Despite this, the company remains committed to its disagreement with the decision. These are some of the recent developments that offer insights into Natera's current status and progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.